United Capital Management of KS Inc. Sells 100 Shares of Eli Lilly and Company (NYSE:LLY)

United Capital Management of KS Inc. trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,272 shares of the company’s stock after selling 100 shares during the quarter. Eli Lilly and Company comprises approximately 2.2% of United Capital Management of KS Inc.’s investment portfolio, making the stock its 15th biggest position. United Capital Management of KS Inc.’s holdings in Eli Lilly and Company were worth $9,547,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Lake Street Private Wealth LLC boosted its position in Eli Lilly and Company by 5.7% during the first quarter. Lake Street Private Wealth LLC now owns 8,175 shares of the company’s stock worth $6,360,000 after purchasing an additional 440 shares during the period. Valley National Advisers Inc. lifted its holdings in shares of Eli Lilly and Company by 2.9% during the first quarter. Valley National Advisers Inc. now owns 5,901 shares of the company’s stock worth $4,591,000 after buying an additional 165 shares in the last quarter. TCP Asset Management LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $201,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $40,000. Finally, Leeward Financial Partners LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $304,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LLY shares. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Bank of America reissued a “buy” rating and set a $1,000.00 target price on shares of Eli Lilly and Company in a report on Monday, June 24th. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Finally, JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Eli Lilly and Company Stock Down 0.9 %

Shares of NYSE LLY opened at $898.10 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company has a market cap of $853.56 billion, a price-to-earnings ratio of 132.27, a PEG ratio of 1.96 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $918.50. The stock has a 50-day moving average price of $824.60 and a two-hundred day moving average price of $746.69.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.62 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 858,742 shares of company stock worth $735,573,781. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.